NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Clinical Trials
4.0k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3400 trials with phase data)• Click on a phase to view related trials
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
- Conditions
- Relapsed and/or Refractory Mature T Cell MalignancyPeripheral T-Cell LymphomaAngioimmunoblastic T-cell LymphomaAnaplastic Large Cell LymphomaHepatosplenic T-cell LymphomaMonomorphic Epithelialtropic Intestinal LymphomaEnteropathy Associated T-cell LymphomaCutaneous T-Cell LymphomaMycosis FungoidesSubacute Panniculitis-like T-cell Lymphoma
- Interventions
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT07055477
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
- Conditions
- Locally Recurrent Skin Squamous Cell CarcinomaMetastatic Skin Squamous Cell Carcinoma
- Interventions
- Drug: Amivantamab and Recombinant Human HyaluronidaseProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT07042295
Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome
- Conditions
- Li-Fraumeni Syndrome
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT07032922
- Locations
- 🇺🇸
NCI Shady Grove Campus, Rockville, Maryland, United States
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- Conditions
- Germline MutationMyelodysplastic SyndromesAcute Myeloid Leukemia
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 510
- Registration Number
- NCT07019155
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Imaging ProcedureProcedure: Lumbar Puncture
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT07012044
- Prev
- 1
- 2
- 3
- 4
- 5
- 807
- Next
News
MIT Develops Implantable Device for Automated Glucagon Delivery to Prevent Diabetic Hypoglycemia
MIT engineers have developed an implantable device that automatically administers glucagon to prevent life-threatening hypoglycemic episodes in diabetics, with testing in mice showing blood sugar stabilization within 10 minutes.
Novel Tiancimycin-Based Antibody-Drug Conjugate Shows Promise Against Aggressive Lymphoma
Scientists at The Herbert Wertheim UF Scripps Institute developed a novel antibody-drug conjugate combining tiancimycin, a natural compound from soil microbes, with a "double-decker" antibody targeting CD79b for diffuse large B cell lymphoma treatment.
UCLA Researchers Receive $3.5 Million NIH Grant to Develop Novel Mpox Antivirals Targeting Immune Evasion
UCLA-led researchers received a $3.5 million NIH grant to develop treatments for mpox, focusing on a more virulent strain causing increased deaths among children in the Democratic Republic of Congo.
India Launches First Indigenous Dengue Vaccine Phase 3 Trial with Over 10,000 Participants
The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll.
Quiver Bioscience Secures $2.15M NIH Grant to Develop AI-Powered CNS Drug Safety Platform
Quiver Bioscience received a $2.15 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke to develop an integrated platform for predicting safety of CNS-targeted antisense oligonucleotide therapeutics.
AN2 Therapeutics Completes 200-Patient Study Revealing 40% Mortality Rate in Acute Melioidosis
AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.
KU Medical Center Receives $31 Million NIH Grant to Expand Pediatric Clinical Trial Access in Underserved Areas
The University of Kansas Medical Center received a five-year, $31 million NIH grant to coordinate pediatric clinical trials across 18 rural and underserved sites, marking the largest award in the institution's history.
Oxford Scientists Develop Single-Shot Malaria Vaccine Using Programmable Microcapsule Technology
University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.
TAM Global Appoints Leading Cancer Immunologist Dr. Francesco Marincola as Chief Scientific Officer
TAM Global has appointed Dr. Francesco Marincola, one of the world's most prolific tumor immunologists with over 700 peer-reviewed publications, as Chief Scientific Officer across its expanding healthcare platform.
University of Wisconsin Researchers Develop Personalized Cancer Vaccines Using Pyroptotic Vesicles to Prevent Tumor Recurrence
University of Wisconsin-Madison researchers have developed personalized cancer vaccines using pyroptotic vesicles, tiny sacs from dying cancer cells, that significantly extended survival in mouse models of triple-negative breast cancer and melanoma.